Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Cash Flow Statement

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	10.44	8.78	9.08	7.08	8.29
Depreciation & Amortization	1.01	0.61	0.51	0.6	0.41
Asset Writedown & Restructuring Costs	-	-	0.34	-	-
Stock-Based Compensation	0.24	0.44	0.68	0.71	0.21
Provision & Write-off of Bad Debts	-0.03	0.14	-0.01	0.01	0.01
Other Operating Activities	1.42	0.11	-0.66	0.66	-0.04
Change in Accounts Receivable	-1.64	-0.78	-2.24	-1.86	-0.18
Change in Inventory	1.52	-5.45	4.26	-4.1	-4.18
Change in Accounts Payable	1.34	2.06	0.99	0.84	1.63
Change in Income Taxes	1.03	0.51	0.04	-0.93	0.07
Change in Other Net Operating Assets	2.48	0.02	0.16	0.08	0.04
Operating Cash Flow	16.43	6.16	12.98	2.78	5.89
Operating Cash Flow Growth	166.87%	-52.59%	367.82%	-52.88%	-21.94%
Capital Expenditures	-0.57	-0.2	-0.66	-0.14	-0.16
Investing Cash Flow	-0.57	-0.2	-0.66	-0.14	-0.16
Long-Term Debt Repaid	-0.77	-0.29	-0.17	-0.34	-1.53
Net Debt Issued (Repaid)	-0.77	-0.29	-0.17	-0.34	-1.53
Issuance of Common Stock	-	3.86	0.87	0.58	0.04
Repurchase of Common Stock	-2.24	-1.39	-0.21	-0.31	-
Common Dividends Paid	-6.08	-5.17	-3.37	-3.04	-2.9
Financing Cash Flow	-9.09	-2.99	-2.88	-3.11	-4.39
Foreign Exchange Rate Adjustments	0.19	1.01	-0.51	0.26	0.07
Net Cash Flow	6.96	3.97	8.94	-0.21	1.42
Free Cash Flow	15.86	5.96	12.32	2.64	5.73
Free Cash Flow Growth	166.17%	-51.66%	367.45%	-54.03%	-23.09%
Free Cash Flow Margin	17.00%	7.49%	16.78%	3.94%	10.04%
Free Cash Flow Per Share	0.28	0.11	0.23	0.05	0.11
Cash Interest Paid	-	0.05	0.06	-	-
Cash Income Tax Paid	2.97	3.36	3.34	4.33	2.88
Levered Free Cash Flow	14.11	4.43	11.18	1.91	4.66
Unlevered Free Cash Flow	14.18	4.46	11.21	1.91	4.7
Change in Working Capital	3.35	-3.93	3.04	-6.3	-2.99

Source: S&P Global Market Intelligence. Standard template. Financial Sources.